Solution using Stomahesive® wafers for allergic contact dermatitis caused by isobornyl acrylate in glucose monitoring sensors.

Autor: Ng KL; Skin Health Institute, Carlton, Victoria, Australia., Nixon RL; Occupational Dermatology and Research and Education Centre, Skin Health Institute, Carlton, Victoria, Australia., Grills C; Royal Children's Hospital, Parkville, Victoria, Australia., Tam MM; Skin Health Institute, Carlton, Victoria, Australia.
Jazyk: angličtina
Zdroj: The Australasian journal of dermatology [Australas J Dermatol] 2022 Feb; Vol. 63 (1), pp. e56-e59. Date of Electronic Publication: 2021 Jul 27.
DOI: 10.1111/ajd.13675
Abstrakt: Isobornyl acrylate (IBOA) has recently caused a number of cases of allergic contact dermatitis (ACD) from its use in medical devices. We would like to enhance the awareness of this issue with the reporting of three Australian cases, involving two adults and a child. We also report a successful solution by using hydrocolloid wafer (Stomahesive®) as a barrier. As IBOA is not usually found on baseline patch test series and does not cross-react with other acrylic monomers, ACD to IBOA may be missed by clinicians.
(© 2021 Australasian College of Dermatologists.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje